Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Velasco

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Science (New York, N.Y.)|September 5, 2024
In vivo dendritic cell reprogramming for cancer immunotherapyErvin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, et al.
Pharmacological Research|July 20, 2023
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in childrenPaula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, et al.
Science Immunology|July 7, 2023
Restoring tumor immunogenicity with dendritic cell reprogrammingOlga Zimmermannova, Alexandra G Ferreira, Ervin Ascic, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 9, 2022
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHANAnat Yerushalmy-Feler, Gemma Pujol-Muncunill, Javier Martin-de-Carpi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 24, 2024
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatmentSara Salvador-Martín, Gianluca Rubbini, Perceval Vellosillo, et al.
International Journal of Molecular Sciences|January 21, 2023
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease CohortSara Salvador-Martín, Paula Zapata-Cobo, Marta Velasco, et al.
European Journal of Pediatrics|April 21, 2021
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish studyRuth Garcia-Romero, José Miguel Martinez de Zabarte Fernandez, Gemma Pujol-Muncunill, et al.
Pharmaceutics|January 12, 2021
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel DiseaseSara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, et al.
Journal of Crohn'S & Colitis|November 28, 2024
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter StudyAnat Yerushalmy-Feler, Elizabeth A Spencer, Michael T Dolinger, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2025
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective StudyShlomi Cohen, Elizabeth A Spencer, Michael T Dolinger, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Science (New York, N.Y.)|September 5, 2024
In vivo dendritic cell reprogramming for cancer immunotherapyErvin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, et al.
Pharmacological Research|July 20, 2023
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in childrenPaula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, et al.
Science Immunology|July 7, 2023
Restoring tumor immunogenicity with dendritic cell reprogrammingOlga Zimmermannova, Alexandra G Ferreira, Ervin Ascic, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 9, 2022
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHANAnat Yerushalmy-Feler, Gemma Pujol-Muncunill, Javier Martin-de-Carpi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 24, 2024
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatmentSara Salvador-Martín, Gianluca Rubbini, Perceval Vellosillo, et al.
International Journal of Molecular Sciences|January 21, 2023
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease CohortSara Salvador-Martín, Paula Zapata-Cobo, Marta Velasco, et al.
European Journal of Pediatrics|April 21, 2021
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish studyRuth Garcia-Romero, José Miguel Martinez de Zabarte Fernandez, Gemma Pujol-Muncunill, et al.
Pharmaceutics|January 12, 2021
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel DiseaseSara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, et al.
Journal of Crohn'S & Colitis|November 28, 2024
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter StudyAnat Yerushalmy-Feler, Elizabeth A Spencer, Michael T Dolinger, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2025
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective StudyShlomi Cohen, Elizabeth A Spencer, Michael T Dolinger, et al.
Pageof 6